Danicamtiv
Sponsors
Myokardia Inc., Myokardia Inc., Kardigan Inc., Bristol-Myers Squibb, Kardigan, Inc.
Conditions
Healthy ParticipantsHealthy VolunteersHeart Failure With Reduced Ejection FractionPrimary Dilated Cardiomyopathy Due to Either MYH7 o TTN VariantsPrimary Familial Dilated CardiomyopathySymptomatic Genetic Dilated CardiomyopathySymptomatic Genetic Dilated Cardiomyopathy (DCM)Symptomatic genetic and familial dilated cardiomyopathy.
Phase 1
A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants
CompletedNCT05162222
Start: 2021-12-15End: 2022-07-08Updated: 2022-08-10
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants
CompletedNCT05806359
Start: 2023-03-31End: 2023-08-14Updated: 2024-05-23
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
CompletedNCT05952089
Start: 2023-08-17End: 2024-03-19Updated: 2024-04-04
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
CompletedNCT06027437
Start: 2023-09-05End: 2023-11-10Updated: 2023-11-29
Phase 2
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
TerminatedNCT04572893
Start: 2020-08-04End: 2024-02-22Updated: 2025-05-21
AN OPEN-LABEL, EXPLORATORY STUDY OF THE SAFETY AND PRELIMINARY EFFICACY OF DANICAMTIV IN STABLE AMBULATORY PARTICIPANTS WITH PRIMARY DILATED CARDIOMYOPATHY DUE TO EITHER MYH7 OR TTN VARIANTS OR OTHER CAUSALITIES
CompletedCTIS2023-505492-68-00
Start: 2020-10-06End: 2024-01-23Target: 21Updated: 2024-02-05
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
RecruitingNCT07210723
Start: 2026-02-13End: 2028-01-01Target: 332Updated: 2026-08-04
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).
Not yet recruitingCTIS2025-522553-19-00
Target: 18Updated: 2026-01-30